window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

non-small cell lung cancer

  • Cell & Gene Therapy,Clinical Development,Oncology,Technology and platforms

    N4 Pharma and SRI demonstrate targeted Nuvec delivery to lung cancer cells

    N4 Pharma has reported new data from its collaboration with [...]

    September 24, 2025
  • Cell & Gene Therapy,Pharmaceuticals and therapeutics,Research & Development,RNA Therapeutics,Technology and platforms

    N4 Pharma advances targeted RNA delivery with SRI collaboration

    N4 Pharma plc, the UK biotech developing its proprietary Nuvec® [...]

    September 23, 2025
  • Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Precision medicine,Real world evidence

    Cemiplimab plus chemotherapy shows five-year survival benefit in advanced NSCLC Empower-lung 3 trial

    Regeneron UK Limited has reported five-year follow-up results from the [...]

    September 10, 2025
  • Clinical Trials

    ctDNA shown to strongly correlate with treatment outcomes across tumor types, study finds

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top